MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Foscarbidopa/Foslevodopa Therapy Improves Continuous Duration of Good ON Time and Correlated With Quality of Life in People With Parkinson’s Disease

    M. Bouchard, R. Hauser, P. Odin, D. Kern, S. Isaacson, L. Bergmann, L. Harmer, J. Homola, R. Gupta, C. Yan, C. Carroll (North Chicago, USA)

    Objective: To assess the impact of foscarbidopa/foslevodopa (CDp/LDp) continuous subcutaneous infusion (CSCI) on longest consecutive duration of Good and Best ON time and association of…
  • 2025 International Congress

    Proof-of-Concept Study Design Leveraging Digital Biomarkers to Enhance Statistical Power and Reduce Sample Size in PD Trials

    S. Hendrix, J. Christensen, S. Jackson, P. O'Keefe, K. Hendrix, S. Dheerendra, F. Nahab, S. Dickson (Millcreek, USA)

    Objective: Parkinson's disease clinical studies for disease modifying therapies face challenges of large sample size and long study duration due to subtle changes at early…
  • 2025 International Congress

    Physiological assessment of swallowing related muscles in patients with Parkinson’s disease: characteristics and utility of high-density surface electromyography

    M. Nakamori, K. Yoshikawa, Y. Nishikawa, M. Toko, H. Yamada, H. Maruyama (Hiroshima, Japan)

    Objective: The study focused on high-density surface electromyography (HD-sEMG) as a novel method to understand the electrophysiological characteristics of swallowing-related muscles in patients with Parkinson's…
  • 2025 International Congress

    Remote Deep Brain Stimulation Programming for Parkinson’s Disease: A Multicenter Randomized Non-Inferiority Trial

    J. Shaik, V. Zentsch, C. Buhmann, T. Kinfe, M. Regensburger, J. Rumpf, A. Schnitzler, G. Höglinger, J. Mehrkens, T. Koeglsperger (Muenster, Germany)

    Objective: To evaluate the effectiveness and safety of remote vs. on-site DBS programming in Parkinson’s disease patients with STN-DBS. Background: Deep brain stimulation (DBS) is…
  • 2025 International Congress

    Random-Order Crossover Trial Assessing the Safety, Feasibility and Exploratory Efficacy of Two Mediterranean-Ketogenic Nutritional Interventions in Parkinson’s Disease

    K. Tosefsky, J. Lam, Y. Wang, A. Kuan, S. Appel-Cresswell (Vancouver, Canada)

    Objective: Assess the feasibility, safety and exploratory efficacy of two Mediterranean-ketogenic dietary interventions in individuals with Parkinson’s disease (PD). Background: Both Mediterranean and ketogenic diets…
  • 2025 International Congress

    Improvements in Motor and Non-Motor Symptoms of Parkinson’s Disease in Those Treated with Photobiomodulation Plus Exercise: A Sham-Controlled Study

    A. Saltmarche, O. Hares, A. Liebert, B. Bicknell, M. Naeser, G. Heller, J. Sykes, K. Togeretz, A. Namini, G. Herkes (Toronto, Canada)

    Objective: To assess efficacy of photobiomodulation + exercise to improve Parkinson’s disease (PD) symptoms. The primary outcome measure was timed up-and-go (TUG) and other motor…
  • 2025 International Congress

    Investigating the cellular consequences of the G2385R LRRK2 variant

    P. Lewis, S. Herbst (London, United Kingdom)

    Objective: The objective of this study is to characterise the biochemical and cellular impact of the G2385R coding variant in LRRK2, a risk variant for…
  • 2025 International Congress

    Does the cerebellum compensate to enable motor learning in Parkinson’s Disease?

    PC. Iyer, BE. Fisher (Los Angeles, USA)

    Objective: To test the causal relation between cerebellar function and learning in PD. Background: Neuroimaging studies reveal that people with Parkinson’s disease (PwPD) exhibit increased…
  • 2025 International Congress

    L-DOPA Induced Iron Accumulation in the Ventral Midbrain: The Roles of Sex and Iron Repletion

    R. Serpa, K. Palsa, E. Tufano, T. Helmuth, S. Mills-Huffnagle, M. Kant, J. Connor (Hershey, USA)

    Objective: This study aims to investigate the impact of L-3,4-dihydroxyphenylalanine (L-DOPA) on ventral midbrain (VMB) iron levels under iron deficiency (ID) and repletion (IR) conditions…
  • 2025 International Congress

    Effect of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on motor fluctuations, dyskinesia, and sleep; subjective vs. PKG watch recordings.

    M. Bradley, E. Donlon, A. Gallagher, C. O'Keefe, J. Inocentes, F. Ruggieri, R. Reilly, R. Walsh, T. Lynch, C. Fearon (Dublin, Ireland)

    Objective: To evaluate the impact of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa on bradykinesia, dyskinesia, and sleep quality using self-reported Hauser diaries and Parkinson’s KinetiGraph…
  • « Previous Page
  • 1
  • …
  • 83
  • 84
  • 85
  • 86
  • 87
  • …
  • 181
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley